Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Cardiovascular biomarkers in clinical studies of type 2 diabetes

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{c126251505574e6397cdf191a76d23fa,
title = "Cardiovascular biomarkers in clinical studies of type 2 diabetes",
abstract = "When planning cardiovascular studies in type 2 diabetes, selection of cardiovascular biomarkers is a complex issue. Since the pathophysiology of cardiovascular disease in type 2 diabetes is multifactorial, ideally, the selected cardiovascular biomarkers should cover all aspects of the known pathophysiology of the disease. This will allow the researcher to distinguish between effects on different aspects of the pathophysiology. To this end, we will discuss a host of biomarkers grouped according to their role in the pathogenesis of CV disease, namely: 1) cardiac damage biomarkers 2) inflammatory biomarkers and 3) novel biomarkers (oxidative stress and endothelial dysfunction biomarkers). Within each category we present the currently best validated biomarkers with special focus on the population of interest (type 2 diabetes). For each individual biomarker, the physiological role, the validation in the general population and in type 2 diabetes, analytical methodology, the modifying factors, the effects of glucose-lowering drugs, and the interpretation are discussed. This approach will provide clinical researchers with all information necessary for planning, conducting and interpreting results from clinical trials. Furthermore, a systematic approach to selection of cardiovascular biomarkers in type 2 diabetes research will improve the quality of future research.",
keywords = "Journal Article, Review",
author = "Baldassarre, {M P A} and A Andersen and A Consoli and Knop, {F K} and T Vilsb{\o}ll",
note = "This article is protected by copyright. All rights reserved.",
year = "2018",
month = "6",
doi = "10.1111/dom.13247",
language = "English",
volume = "20",
pages = "1350–1360",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "6",

}

RIS

TY - JOUR

T1 - Cardiovascular biomarkers in clinical studies of type 2 diabetes

AU - Baldassarre, M P A

AU - Andersen, A

AU - Consoli, A

AU - Knop, F K

AU - Vilsbøll, T

N1 - This article is protected by copyright. All rights reserved.

PY - 2018/6

Y1 - 2018/6

N2 - When planning cardiovascular studies in type 2 diabetes, selection of cardiovascular biomarkers is a complex issue. Since the pathophysiology of cardiovascular disease in type 2 diabetes is multifactorial, ideally, the selected cardiovascular biomarkers should cover all aspects of the known pathophysiology of the disease. This will allow the researcher to distinguish between effects on different aspects of the pathophysiology. To this end, we will discuss a host of biomarkers grouped according to their role in the pathogenesis of CV disease, namely: 1) cardiac damage biomarkers 2) inflammatory biomarkers and 3) novel biomarkers (oxidative stress and endothelial dysfunction biomarkers). Within each category we present the currently best validated biomarkers with special focus on the population of interest (type 2 diabetes). For each individual biomarker, the physiological role, the validation in the general population and in type 2 diabetes, analytical methodology, the modifying factors, the effects of glucose-lowering drugs, and the interpretation are discussed. This approach will provide clinical researchers with all information necessary for planning, conducting and interpreting results from clinical trials. Furthermore, a systematic approach to selection of cardiovascular biomarkers in type 2 diabetes research will improve the quality of future research.

AB - When planning cardiovascular studies in type 2 diabetes, selection of cardiovascular biomarkers is a complex issue. Since the pathophysiology of cardiovascular disease in type 2 diabetes is multifactorial, ideally, the selected cardiovascular biomarkers should cover all aspects of the known pathophysiology of the disease. This will allow the researcher to distinguish between effects on different aspects of the pathophysiology. To this end, we will discuss a host of biomarkers grouped according to their role in the pathogenesis of CV disease, namely: 1) cardiac damage biomarkers 2) inflammatory biomarkers and 3) novel biomarkers (oxidative stress and endothelial dysfunction biomarkers). Within each category we present the currently best validated biomarkers with special focus on the population of interest (type 2 diabetes). For each individual biomarker, the physiological role, the validation in the general population and in type 2 diabetes, analytical methodology, the modifying factors, the effects of glucose-lowering drugs, and the interpretation are discussed. This approach will provide clinical researchers with all information necessary for planning, conducting and interpreting results from clinical trials. Furthermore, a systematic approach to selection of cardiovascular biomarkers in type 2 diabetes research will improve the quality of future research.

KW - Journal Article

KW - Review

U2 - 10.1111/dom.13247

DO - 10.1111/dom.13247

M3 - Review

VL - 20

SP - 1350

EP - 1360

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 6

ER -

ID: 52758782